Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report report published on Friday morning. The firm issued a hold rating on the stock.

Other equities analysts also recently issued reports about the company. Lake Street Capital decreased their price target on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a research report on Tuesday, March 4th.

Ekso Bionics Trading Down 9.7 %

Shares of EKSO opened at $0.38 on Friday. Ekso Bionics has a one year low of $0.34 and a one year high of $1.53. The stock has a 50-day moving average price of $0.50 and a 200 day moving average price of $0.71. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The company has a market capitalization of $9.38 million, a P/E ratio of -0.58 and a beta of 1.33.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The business had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. Sell-side analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.